NCT02981576View on ClinicalTrials.gov

Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

May 5, 2018

Study Completion Date

January 20, 2019

Conditions
Spinal Cord Injuries
Interventions
BIOLOGICAL

Autologous Mesenchymal Stem Cells

Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.

Trial Locations (1)

11942

Cell Therapy Center, University of Jordan, Amman

All Listed Sponsors
lead

University of Jordan

OTHER

NCT02981576 - Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients. | Biotech Hunter | Biotech Hunter